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Remarks to the Author: 
Review of “Multi-omics integration analysis identifies novel genes for alcoholism with potential link to 
neurodegenerative diseases” by Kapoor et al. 
 
The authors perform fine mapping of GWAS risk loci for alcohol use disorder (AUD) and drinks per 
week (DPW) using “multi-omics” approaches including Summary based Mendelian Randomization 
(SMR). SMR uses GWAS summary statistics and mQTL/eQTL data from fetal and adult brains to 
identify causal variants/genes. They identified several risk genes and fine-map/discuss in particular 
two loci; one on chromosome 11 (implicating SPI1 in both AUD and DPW) and one on chromosome 17 
(implicating MAPT in DPW). 
Additionally, the authors take their findings further and validate their SMR results for MAPT in 
expression data from post-mortem brain samples from individuals with AUD and controls. 
 
This study represents a nice step towards further biological understanding of GWAS risk loci for AUD 
and DWP. Additionally, the authors have generated an online tool where readers can visualize the 
findings. I think this a great way to give readers the opportunity to look further into the results. I am 
positive about this study, however I still have some comments: 
 
1) The authors use an FDR < 20% to claim significance in the SMR analyses. I could worry that this 
threshold is too liberal and additionally (at least to my understanding) the authors do provide any 
correction for the number tissues (adult or fetal brain) and type of regulatory variant (eQTL or mQTL). 
 
2) In table 1a. and 1.b – what are the criteria for a gene to be included? Is it all genes with FDR < 
20% in one of the analyzed tissues? – please add this information to the table legends and add 
information about what the “Diff_exp P value” represents. 
 
3) The authors write “..mRNA expression of MAPT was associated with increased alcohol consumption 
(Figure 2c)” correct the text to (Figure 4c). 
 
4) In the analysis testing for difference in expression of MAPT in postmortem brains of AUD cases and 
controls the authors report a significant association, however this is not significant after Bonferroni 
correction when correcting for the 61 genes reported in Table 2a. The results could also be validated 
using another bioinformatic method, such as doing sPrediXcan using models trained on brain tissues 
to test for association of gene expression with DPW. 
 
5) In the pathway analyses – please give information about the number of pathways tested. I assume 
no pathways survive Bonferroni correction, instead the authors provide an FDR of 20%, and again I 
think this is very liberal in order to claim real significance. I would at least moderate the wording to 
state “suggestive significance” or something similar in the text. 
 
6) At several places the authors write “AUD GWAS”, I assume they refer to the AUD GWAS meta-
analysis that they perform, but this is not clear. So please correct this to “AUD GWAS meta-analysis” 
throughout the text, when relevant. 
 
7) In the introduction the authors write “DPW is genetically uncorrelated with most psychiatric 
disorders (except ADHD and tobacco use disorder) but correlated negatively with educational 
achievement and cardio-metabolic disease (which remains uncorrelated with PAU or AUD)”. In the 
GSCAN paper DPW has a non-significant genetic correlation with educational attainment of rg=0.01 
(including 23andMe individuals in the DPW sample), and Kranzler et al. found a positive genetic 
correlation between alcohol consumption and educational attainment. So could the authors check if 





Remarks to the Author: 
The focus of this work is to integrate -omics data (expression, methylation) with genome wide 
association study (GWAS) results for the two outcomes of alcohol use disorder (AUD) and drinks per 
week (DPW) to try to understand the functional significance of variants and determine causal 
candidate genes. It is novel in that it is the largest muli-omcs integration of these two outcomes, and 
will be of interest to the psychiatric and genetics research community. This is an impressive amount of 
work managing many different data sets and provides a candidate loci of interest. The main concerns 
were with the stated goals of a simultaneous approach for both outcomes, whether ancestry was 
addressed, and the presentation of the manuscript. 
 
 
1. The introduction claims that this is an integrated approach and looks at the two phenotypes AUD 
and DPW “specifically as well as simultaneously.” But it seems like most of the analyses examine AUD 
and DPW separately, then look later for overlap. For example the LDSC analysis seems to be 
completely separate, and not much discussion about overlap. Can the authors do more direct analysis 
(e.g. SNPs that intersect for the two outcomes) for a more integrative and simultaneous approach at 
later stages? Or they may need to downplay this description. 
 
2. Ancestry is not discussed but there appears to be both European and African ancestry populations 
in the meta-analysis GWAS. But for the various e/mQTL meta-analysis performed by the authors and 
others, how similar are those populations to the populations used in the meta-analysis GWAS? Is 
ancestry adjusted for in any of the analyses? (GWAS, QTL, differential expression, etc) 
 
3. Other concerns were about the presentation regarding enough detail for reproducibility and the 
statistical analysis. Since space is constrained, a supplemental materials/methods would help, in 
addition to improved organization of the figures/tables and supplemental figures/tables. 
 
a. Although it may be obvious to some, it’s still important to define all abbreviations (e.g, EUR, AFR, 
RIN). Also what is PMI? Is that supposed to be BMI? 
 
b. What meta-analysis method is used fo the “eQTL meta-analysis in adult brain”? e.g., random-
effects, etc. In general, for all of the meta-analyses, more detail would be important regarding the 
method, populations, sample sizes. 
 
c. The numbering of the tables/figures are off. For example, Supplementary Table 1 seems to be 2, 
and Figures 2 and 3 seem to be 4 and 5 respectively. Other times Supplemental Figures and Tables 
are referred to in the text, but with no number. 
 
d. There is a file of additional supplementary figures that are not described and did not appear to be 
referenced. They should not be included if not cited specifically. 
 
e. The manuscript states “A large proportion (45%) of AUD and DPW associated SNPs were within 
intronic, UTR and non-coding regions of the genome.” Is this percentage expected by chance? 
 
f. Figure 6 seems unnecessary as a figure, the content can be displayed as a table or even in the text. 
 
g. In the methods, please provide p-value or FDR cutoffs used in the different analyses. Is multiple 
testing adjustment performed for the differential expression analysis? 
 
h. Can a similar figure relating MAPT gene expression to DPW as in Figure 4C, be performed for the 





Remarks to the Author: 
This comprehensive analysis of existing human 'omics data relevant to the understanding of alcohol 
use disorder provides some replication of previously identified genes and evidence for novel 
associations. The manuscript is clearly written so it is easy to follow the different datasets and 
analyses conducted. The statistical methods applied are appropriate and rigorous. It represents a 
significant advancement for the field of alcohol genomics and should inspire basic scientists to 
prioritize some of these genes for further study. 
 
Some questions and suggestions: 
 
1) Title: It is not clear to me why a reference to neurodegenerative diseases merits mention in the 
title. It's not irrelevant, but I don't feel the results strongly point in this direction, or at least the way 
presented in the paper it is not emphasized. 
 
2) Introduction, para 2: I do not understand why the authors refer to the Zhou et al paper (ref 10) as 
the "largest tranche of signals for any addictive disorder to date". In the very next sentence they refer 
to the Liu et al paper (ref 11) which included a larger sample and identified more loci/genes. 
 
3) The emergence of SP11 and NUP160 as potentially important genes is interesting, especially given 
their high expression in myeloid cells. My colleagues who are experts in the connections between 
immunology and neurobiology have often questioned why we do not use perfusion for animal studies 
of mouse/rat brain for various RNA sequencing experiments. Their reasoning is that if you simply flash 
freeze the brains and use tissue from that, you will inevitably be assessing a lot of blood cells, not 
neuronal cells. Obviously, with human brains, perfusion is not possible. But this makes it difficult to 
interpret results where the genes involved may be more likely reflect changes in blood cells than 
neuronal cells. This is not to say such changes aren't important, but it seems some discussion is 
necessary to help the reader hypothesize how such changes may be functionally relevant to what is 
being studied in this context as a "brain" disease. This is more of a "big-picture" question, because as 
the authors point out in the discussion, other studies have identified an important role of immune 
networks in drinking behaviors (ref 25-31). 
 
4) Minor point: Discussion, para 5 that begins, "We also identified other genes..." The word "also" 
occurs several times so the authors may wish to rework some of the writing. 
 
5) I did not see any specific discussion about whether the authors attempted to identify possible sex 
differences for any of the analyses. It appeared to be included as a covariate for most or all, but in 
some cases it seems like they may have enough power to separate the sample by sex. Given the 
known sex differences in AUD, this has the potential to be very interesting and would add something 
new to the field. While the current paper is a fantastic effort and integration, it's really just adding 
more genes on top of other genes from previous 'omics studies, so a sex-specific analysis would add 
something new. 
 
Along these lines, it would be useful for the authors to identify the genes in their tables that are new 
with this analysis and haven't emerged from previous publications. I don't say this to imply that I 
don't believe they've found anything new - I agree there is lots of great new stuff here. But it would 
really help the reader be able to distinguish which pieces are new and which genes now have lots of 
evidence for involvement in AUD. 
 
6) I really like the use of ShinyApp to allow others to query the database and view the results. 
However, it would be useful to add a section that clearly describes under a single heading where each 
of the datasets can be found, so that others could obtain the raw data for themselves. 
 
7) This paper is limited to data collected from human studies. There would value in adding a 
paragraph or two in the discussion about genes identified in animal models. Unfortunately, I don't 
think a recent GeneWeaver analysis has been published for alcohol phenotypes, but I think Rohan 
Palmer's group has been working on it. 
REVIEWER COMMENTS 
 
We thank all three reviewers for their constructive critiques, that further enhance the quality of 
our manuscript. We have made several changes according to the reviewers’ comments. A point-
by-point response to the comments is provided below, with the resulting changes to the 
manuscript. 
 
Reviewer #2 (Remarks to the Author): 
This study represents a nice step towards further biological understanding of GWAS risk loci for 
AUD and DWP. Additionally, the authors have generated an online tool where readers can 
visualize the findings. I think this is a great way to give readers the opportunity to look further 
into the results. I am positive about this study, however I still have some comments: 
We thank the reviewer for the positive statements.  
 
1) The authors use an FDR < 20% to claim significance in the SMR analyses. I could worry that 
this threshold is too liberal and additionally (at least to my understanding) the authors do provide 
any correction for the number tissues (adult or fetal brain) and type of regulatory variant (eQTL 
or mQTL).  
 
Ans: The SMR analysis is after we have already filtered our GWAS and eQTL summary 
statistics on strict P values thresholds, not the only threshold used. The reported genes in 
the integration analyses survived four different P value thresholds to be nominated as 
potential causal genes (GWAS P <= 5 x 10-5; e/mQTL P <= 5 x 10-8; Heidi P >= 0.05; 
SMR FDR <= 0.2). Thus the FDR values for SMR P are still conservative for identifying 
novel targets. Further, due to the complex LD structure at several loci many genes at a 
locus had similar correlated P values. Applying a more restrictive per gene FDR (without 
other threshold criteria) would have prioritized all genes at the few most significant loci, 
rather than prioritizing top candidate genes across the larger set of loci. For these reasons, 
we used restrictive thresholds for the initial steps and more liberal thresholds to report the 
final set of variants. We have noted this point under table 1 and 2. We have also noted 
above mentioned text in the result section. 
 
2) In table 1a. and 1.b what are the criteria for a gene to be included? Is it all genes with FDR < 
20% in one of the analyzed tissues? Please add this information to the table legends and add 
information about what the Diff_exp P value represents. 
 
Ans: Genes reported in the integration analyses survived four different P value thresholds 
to be nominated as potential causal genes (GWAS P <= 5 x 10-5; e/mQTL P <= 5 x 10-8 ; 
Heidi P >= 0.05; SMR FDR <= 0.2). This is now noted under each table.  
 
 
3) The authors write mRNA expression of MAPT was associated with increased alcohol 
consumption (Figure 2c), correct the text to (Figure 4c). 
 
Ans: We have corrected the text. 
 
 
4) In the analysis testing for difference in expression of MAPT in postmortem brains of AUD 
cases and controls the authors report a significant association, however this is not significant 
after Bonferroni correction when correcting for the 61 genes reported in Table  
 
Ans: We agree that differential expression results will not survive multiple test correction. 
Although the differential expression results from brains of alcoholics and controls were 
generated on the largest dataset available to date (N = 138 total; alcohol consumption 
data for 92 brains), the small effect sizes of GWAS signals would require a much larger 
brain dataset to detect association of SNP mediated mRNA expression changes with the 
phenotype. For example, if we assume that SNP mediated expression is increasing the 
expression in alcoholics by 1.2 times (FC = 1.2; larger than most variants), then it requires 
data from at-least 200 brains (alcoholics + controls) to detect large number of association 
at FDR 0.05 (calculated using R package “ssizeRNA”). Despite this limitation our data 
prioritized key genes that were nominally associated, which is encouraging for further 
targeted studies. We have moderated the wording in the text that the association of MAPT 
in the independent dataset was replicated at a nominal significance level. We have also 
added the above-mentioned statement as a limitation of the study (Page 10; Lines 321-
326). 
 
2a. The results could also be validated using another bioinformatic method, such as doing 
sPrediXcan using models trained on brain tissues to test for association of gene expression with 
DPW. 
 
We used the Transcriptome wide association analysis (TWAS) method to validate the 
results. Unlike prediXcan, TWAS uses multiple methods to predict the gene expression 
weights and outputs the results of the best prediction method. The TWAS analysis using the 
CommonMind eQTL dataset as a reference prioritized MAPT (TWAS P = 1.69 x 10-12) as 
one of the strongest candidates in the 17q.21.31 locus. In comparison, the SMR p value for 
MAPT using our largest eQTL meta-analysis was slightly stronger (SMR P = 4.84 x 10-16). 
 
We also specifically want to point out that PrediXcan and TWAS have a small drawback. 
These methods require raw eQTL/ mQTL datasets to create the prediction models. Due to 
this caveat these methods are restricted to a smaller number of datasets for which the raw 
data or prediction weights are available (e.g. GTEx brain, CommonMind brains). Using 
the SMR method we were able to meta-analyze summary statistics from all large brain 
eQTL datasets and use it as a reference, boosting the power of our integration analyses. 
The TWAS results for MAPT locus are available as supplementary table 7 for comparison. 
The complete TWAS summary statistics will be available to download from the GitHub 
link. 
 
5) In the pathway analyses please give information about the number of pathways tested. I 
assume no pathways survive Bonferroni correction, instead the authors provide an FDR of 20%, 
and again I think this is very liberal in order to claim real significance. I would at least moderate 
the wording to state suggestive significance or something similar in the text. 
 
Ans: In all, 410 pathways were tested using IPA and none of the pathway survived 
threshold for multiple test correction (PBonferroni = 1.2 x 10-4). Ingenuity Pathway Analysis 
of the prioritized genes associated with DPW showed suggestively significant enrichment 
for pathways related to TR (Thyroid hormone receptor)/RXR (Retinoic X receptor) 
activation (P = 1.45 x 10-4), and Lipoate biosynthesis (3.29 x 10-4),  which are very close 
to the threshold for Bonferroni correction.  
 
We have also moderated the text to “suggestive significance” according to the reviewer’s 




6) At several places the authors write AUD GWAS, I assume they refer to the AUD GWAS meta-
analysis that they perform, but this is not clear. So please correct this to AUD GWAS meta-analysis 
throughout the text, when relevant. 
 




7) In the introduction the authors write DPW is genetically uncorrelated with most psychiatric 
disorders (except ADHD and tobacco use disorder) but correlated negatively with educational 
achievement and cardio-metabolic disease (which remains uncorrelated with PAU or AUD). In 
the GSCAN paper DPW has a non-significant genetic correlation with educational attainment of 
rg=0.01 (including 23andMe individuals in the DPW sample), and Kranzler et al. found a 
positive genetic correlation between alcohol consumption and educational attainment. So could 
the authors check if the sentence instead should be “but correlated positively with educational 
achievement”. 
 
Ans: We thank the reviewer for pointing this out, and we have corrected the sentence to 




Reviewer #3 (Remarks to the Author): 
 
The focus of this work is to integrate -omics data (expression, methylation) with genome wide 
association study (GWAS) results for the two outcomes of alcohol use disorder (AUD) and 
drinks per week (DPW) to try to understand the functional significance of variants and determine 
causal candidate genes. It is novel in that it is the largest multi-omics integration of these two 
outcomes, and will be of interest to the psychiatric and genetics research community. This is an 
impressive amount of work managing many different data sets and provides candidate loci of 
interest. The main concerns were with the stated goals of a simultaneous approach for both 
outcomes, whether ancestry was addressed, and the presentation of the manuscript.  
 
 
1. The introduction claims that this is an integrated approach and looks at the two phenotypes 
AUD and DPW “specifically as well as simultaneously”.  But it seems like most of the analyses 
examine AUD and DPW separately, then look later for overlap. For example, the LDSC analysis 
seems to be completely separate, and not much discussion about overlap. Can the authors do 
more direct analysis (e.g. SNPs that intersect for the two outcomes) for a more integrative and 
simultaneous approach at later stages? Or they may need to downplay this description. 
 
Ans: The reviewer is correct: the analyses presented in this manuscript performed multi-
omic integration analyses separately for AUD and DPW and only later looked at the 
overlap. We specifically employed this approach as it minimizes the bias in results due to 
large sample size differences between the two GWASs. The extremely large sample size for 
DPW GWAS means that a simultaneous multi-omics analysis would predominantly 
prioritize genes associated with the DPW phenotype. In fact, we used the Multi-Trait 
Analysis of GWAS (MTAG) method to meta-analyze the summary statistics from DPW and 
AUD GWASs. Although this method is robust to correlated multi-trait meta-analysis, the 
SMR analysis using the MTAG results were primarily driven by the DPW variants. To 
reduce the bias, we focused on SMR results from MTAG using our stricter threshold 
(GWAS AUD 5 x 10-5; e/mQTL P 5 x 10-8; SMR P < 20%; Heidi P > 0.05); the results 
were similar to our original SMR results (later overlap analysis). In fact, many SNPs in 
the combined analysis were filtered out due to inflated summary statistics of the 
heterogeneity test (Supplementary table 5).  
 
On the other hand, SMR analysis using individual summary statistics highlighted the 
unbiased association within each dataset. Additionally, the current discussion section 
highlights the strongest overlapping gene (SPI1) that passed the stricter threshold of 
association in DPW and AUD meta-analysis datasets (SMR FDR P < 20%, Heidi P > 0.05, 
GWAS P 5 x 10-8, eQTL/ mQTL P < 5 x 10-8). We have included an additional 
supplementary table (Supp table 6) that includes the overlapping summary statistics from 
AUD and DPW SMR results at relaxed P values. A list of all of the overlapping genes can 
also be visualized on the ShinyApp. The introduction section has been updated to briefly 
mention and justify the approach used in current study (Page 5; Lines 117-122). 
 
2. Ancestry is not discussed but there appears to be both European and African ancestry 
populations in the meta-analysis GWAS. But for the various e/mQTL meta-analysis performed 
by the authors and others, how similar are those populations to the populations used in the meta-
analysis GWAS? Is ancestry adjusted for in any of the analyses? (GWAS, QTL, differential 
expression, etc) 
 
Ans: For the current study we only analyzed the European subset of PGC. Genetically 
calculated PC1 was added in the European subset as well. We have made the changes in 
manuscript to better describe the analyses. The appropriate genetically calculated PCs 
were included in the individual analyses as well. The GWAS analyses in COGA and MVP 
datasets was also limited to European ancestry (Page 11, Lines 348-353).  
 
 
3. Other concerns were about the presentation regarding enough detail for reproducibility and the 
statistical analysis. Since space is constrained, a supplemental materials/methods would help, in 
addition to improved organization of the figures/tables and supplemental figures/tables. 
 
The current analysis primarily used summary statistics from published datasets. We have 
included citations to the original analyses in the methods. We have also included additional 
details for the AUD meta-analyses, COGA-INIA eQTL analysis and eQTL meta-analysis 
for reproducibility. The scripts used for eQTL and SMR analysis have been added to a 
GitHub page (https://github.com/kapoormanav/alc_multiomics) so that others can follow 
and validate the results presented in the manuscript.  
 
We have added additional descriptions/ footnotes in tables and supplementary information 
to improve the organization. 
 
 
a. Although it may be obvious to some, it’s still important to define all abbreviations (e.g, EUR, 
AFR, RIN). Also what is PMI? Is that supposed to be BMI?  
 
Ans: We apologize for not expanding all the abbreviations. PMI is the post-mortem 




b. What meta-analysis method is used for the “eQTL meta-analysis in adult brain” e.g., random-
effects, etc. In general, for all of the meta-analyses, more detail would be important regarding the 
method, populations, sample sizes. 
 
Ans: The meta-analysis for eQTL was performed using an inverse-variance-weighted 
meta-analysis assuming all the cohorts are independent. More details about the method 
can be found here (https://cnsgenomics.com/software/smr/#MeCS). The methods section 
has been updated for all the meta-analyses with appropriate citation to the methods. 
 
 
c. The numbering of the tables/figures are off. For example, Supplementary Table 1 seems to be 
2, and Figures 2 and 3 seem to be 4 and 5 respectively. Other times Supplemental Figures and 
Tables are referred to in the text, but with no number. 
 
Ans: We thank the reviewer for pointing this out. We have made the required changes to 
cite each figure and table properly. 
 
 
d. There is a file of additional supplementary figures that are not described and did not appear to 
be referenced. They should not be included if not cited specifically. 
 
Ans: We thank reviewers for pointing this out. The supplementary figures are 
complementary to the data in the supplementary tables. It was our oversight that we didn’t 
cite these along with these tables. We have now cited all tables and figures. 
 
 
e. The manuscript states “A large proportion (45%) of AUD and DPW associated SNPs were 
within intronic, UTR and non-coding regions of the genome.” Is this percentage expected by 
chance? 
 
Ans: Compared to all variants from the reference genotyping array, the proportion of SNPs 
within intronic, UTR and non-coding regions was suggestively significantly enriched for 
AUD and DPW associated SNPs (P < 5 x 10-2) [Additional supplementary information 
figure 6]. 
 
f. Figure 6 seems unnecessary as a figure, the content can be displayed as a table or even in the 
text. 
 
Ans: The content of the figure is available as supplementary information (supplementary 
table 4) as well. We have removed the figure according to reviewer’s suggestion. 
 
g. In the methods, please provide p-value or FDR cutoffs used in the different analyses. Is 
multiple testing adjustment performed for the differential expression analysis? 
 
Ans: The methods and results section have been updated to emphasize the p-value and 
FDR cut-offs.  The differential expression results listed in table 1b did not pass the 
threshold for multiple test correction due to the small sample size of the post-mortem brain 
dataset (N =92).   The P values were listed as additional information to prioritize the 
candidate genes according to actual changes in gene expression due to alcohol exposure. 
We have added this statement under the table 1b as well. 
 
 
h. Can a similar figure relating MAPT gene expression to DPW as in Figure 4C, be performed 
for the candidate gene SPI1 in Figure 5? 
 
Ans: Unfortunately, we don’t have access to alcohol consumption data in the myeloid cell 
datasets where SPI1 is primarily expressed.  SPI1 expression was not in the detectable 
range in the bulk brain RNA-Seq data from brains of alcoholics, due to the tiny proportion 
of microglia in bulk brain tissues (<5%). As a result, it is not possible to create a similar 
figure for SPI1. 
 
 
Reviewer #4 (Remarks to the Author): 
 
This comprehensive analysis of existing human 'omics data relevant to the understanding of 
alcohol use disorder provides some replication of previously identified genes and evidence for 
novel associations. The manuscript is clearly written so it is easy to follow the different datasets 
and analyses conducted. The statistical methods applied are appropriate and rigorous. It 
represents a significant advancement for the field of alcohol genomics and should inspire basic 
scientists to prioritize some of these genes for further study. 
 
We thank the reviewer for highlighting the salient features of our work. 
 
 
Some questions and suggestions: 
 
1) Title: It is not clear to me why a reference to neurodegenerative diseases merits mention in the 
title. It's not irrelevant, but I don't feel the results strongly point in this direction, or at least the 
way presented in the paper it is not emphasized. 
 
Ans: The top genes identified (SPI1 and MAPT) in this study are also strong candidates 
for Alzheimer disease risk (Huang et al, 2017, PMID: 28628103; Sanchez-Juan et al, 2019, 
PMID: 31866851). MAPT is also a risk gene for progressive supranuclear palsy and 
corticobasal degeneration and a causal gene for Fronto-temporal dementia. Additionally, 
the gene-enrichment analysis demonstrated strong enrichment for neuro-degenerative 
disease associated genes. These observations together led us to believe that there might be 
some connection between alcoholism and neurodegenerative disorders. Since alcoholism 
is more commonly compared to other substance abuse disorders and psychiatric disorders 
we thought it important to point out the largely overlooked overlap with neurodegenerative 
diseases, many of which have behavioral/personality changes as part of the spectrum of 
clinical symptoms.   
 
 
2) Introduction, para 2: I do not understand why the authors refer to the Zhou et al paper (ref 10) 
as the "largest tranche of signals for any addictive disorder to date". In the very next sentence, 
they refer to the Liu et al paper (ref 11) which included a larger sample and identified more 
loci/genes. 
 
Zhou et al. specifically focused on problematic alcohol use which is very highly correlated 
with alcohol use disorder. Liu et al. included a larger sample size but analyzed 
consumption rather than disorder; the genetics of consumption and problematic alcohol 
use or AUD differ. We have added an additional sentence to clarify the differences between 
phenotypes used in the two studies (Page 4: Line 86-90). 
 
 
3) The emergence of SP11 and NUP160 as potentially important genes is interesting, especially 
given their high expression in myeloid cells. My colleagues who are experts in the connections 
between immunology and neurobiology have often questioned why we do not use perfusion for 
animal studies of mouse/rat brain for various RNA sequencing experiments. Their reasoning is 
that if you simply flash freeze the brains and use tissue from that, you will inevitably be 
assessing a lot of blood cells, not neuronal cells. Obviously, with human brains, perfusion is not 
possible. But this makes it difficult to interpret results where the genes involved may be more 
likely reflect changes in blood cells than neuronal cells. This is not to say such changes aren't 
important, but it seems some discussion is necessary to help the reader hypothesize how such 
changes may be functionally relevant to what is being studied in this context as a "brain" disease. 
This is more of a "big-picture" question, because as the authors point out in the discussion, other 
studies have identified an important role of immune networks in drinking behaviors (ref 25-31).  
 
Ans: Reviewer 4 makes an excellent point regarding the gene expression studies from 
human alcoholic brain tissue. Our current study, therefore, is important because we started 
with the genetic predisposition (GWAS) data and asked the question whether the disease 
associated variants alter gene expression in certain tissues and/ or cell types.  While we 
cannot distinguish between brain resident cells and peripheral myeloid cells in our bulk 
RNAseq data from the alcoholic brains, other data point specifically to brain resident 
microglia. For example. using brain specific single cell epigenetic data from 4 major cell 
types (neurons, microglia, astrocytes and oligodendrocytes), we demonstrate that the 
disease associated variants specifically overlap with epigenetic signals microglia (see 
figure 5).  
 
4) Minor point: Discussion, para 5 that begins, "We also identified other genes..." The word 
"also" occurs several times so the authors may wish to rework some of the writing.  
 




5) I did not see any specific discussion about whether the authors attempted to identify possible 
sex differences for any of the analyses. It appeared to be included as a covariate for most or all, 
but in some cases it seems like they may have enough power to separate the sample by sex. 
Given the known sex differences in AUD, this has the potential to be very interesting and would 
add something new to the field. While the current paper is a fantastic effort and integration, it's 
really just adding more genes on top of other genes from previous 'omics studies, so a sex-
specific analysis would add something new. 
 
Ans: We agree with the reviewer that it would be interesting to include sex stratified 
analysis. The current analyses were performed using GWAS and e/mQTL summary 
statistics to boost the power of the analysis. Given the limited availability of sex stratified 
summary statistics and complete raw data of GWAS and e/mQTL data we are not able to 
perform the sex stratified analysis. 
 
Along these lines, it would be useful for the authors to identify the genes in their tables that are 
new with this analysis and haven't emerged from previous publications. I don't say this to imply 
that I don't believe they've found anything new - I agree there is lots of great new stuff here. But 
it would really help the reader be able to distinguish which pieces are new and which genes now 
have lots of evidence for involvement in AUD.  
 
Ans: The superscript N in front of gene name in table 1a and 1b highlights the novel 
candidate causal genes prioritized in this study. 
 
6) I really like the use of ShinyApp to allow others to query the database and view the results. 
However, it would be useful to add a section that clearly describes under a single heading where 
each of the datasets can be found, so that others could obtain the raw data for themselves. 
 
We have added a GitHub link on the app where the summary statistics used in this dataset 
will be downloaded after the publication. 
 
 
7) This paper is limited to data collected from human studies. There would value in adding a 
paragraph or two in the discussion about genes identified in animal models. Unfortunately, I 
don't think a recent GeneWeaver analysis has been published for alcohol phenotypes, but I think 
Rohan Palmer's group has been working on it.  
 
Ans: We agree that data from animal studies might further add confidence to the results of 
the current study. We have provided evidence from animal studies in support of results of 
the current analyses. For example, in the discussion section we have provided evidence 
from animal studies in support of SPI1 as a candidate gene.  Specifically, the following 
three references were noted in support of SPI1 as a candidate gene: 
 
35. Socodato, R. et al. Daily alcohol intake triggers aberrant synaptic pruning leading to 
synapse loss and anxiety-like behavior. Sci Signal 13(2020). 
36. Joshi, P.C. et al. Chronic ethanol ingestion in rats decreases granulocyte-macrophage 
colony-stimulating factor receptor expression and downstream signaling in the alveolar 
macrophage. J Immunol 175, 6837-45 (2005). 
37. Mehta, A.J. et al. Zinc supplementation restores PU.1 and Nrf2 nuclear binding in alveolar 
macrophages and improves redox balance and bacterial clearance in the lungs of alcohol-
fed rats. Alcohol Clin Exp Res 35, 1519-28 (2011). 
 
We have also provided evidence from animal studies in support of MAPT as a candidate 
gene (Hoffmann et al, 2019) 
Hoffman, J.L. et al. Alcohol drinking exacerbates neural and behavioral pathology in the 
3xTg-AD mouse model of Alzheimer's disease. Int Rev Neurobiol 148, 169-230 (2019).  
 
We have added an additional paragraph in the discussion to emphasize the importance of 
validation of human results in vitro and in-vivo. All results from the current analysis will be freely 




Remarks to the Author: 
My main concerns were related to the FDR used in the SMR analyses and lack of significance after 
Bonferroni correction (and their wording related to this) when testing for difference in expression of 
MAPT in postmortem brains. I think the authors have addressed my concerns regarding these two 
points and provided sufficient information regarding my other points. 
 





Remarks to the Author: 





Remarks to the Author: 
The authors have addressed all of my comments. 
